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Summary
Fatigue is a prevalent and substantial phenomenon in many patients with chronic
inflammatory diseases, often rated by patients as the most troublesome symptom
and aspect of their disease. It frequently interferes with physical and social func-
tions and may lead to social withdrawal, long-standing sick leave and disability.
Although psychological and somatic factors such as depression, sleep disorders,
pain and anaemia influence fatigue, the underlying pathophysiological mecha-
nisms by which fatigue is generated and regulated are largely unknown. Increas-
ing evidence points towards a genetic and molecular basis for fatigue as part of
the innate immune system and cellular stress responses. Few studies have focused
on fatigue in dermatological diseases. Most of these studies describe fatigue as a
phenomenon related to psoriatic arthritis and describe the beneficial effects of
biological agents on fatigue observed in clinical studies. It is therefore possible
that this problem has been underestimated and deserves more attention in the
dermatological community. In this review, we provide a definition and explana-
tion for chronic fatigue, describe some commonly used instruments for measur-
ing fatigue, and present hypothetical biological mechanisms with an emphasis on
activation of the innate immune system and oxidative stress. An overview of rele-
vant clinical studies covering the theme ‘psoriasis and fatigue’ is given.
What’s already known about this topic?
• Fatigue is prevalent in patients with chronic inflammatory diseases, cancer and
some neurological diseases.
• Depression, sleep disorders and pain influence fatigue.
• Genes and molecular signalling pathways are increasingly recognized as important
contributors to fatigue.
What does this study add?
• The relationship of fatigue with psoriasis disease activity is unclear.
• Biological drugs have a beneficial effect on fatigue in patients with psoriasis.
• More knowledge regarding the prevalence, severity and impact of fatigue in
patients with psoriasis is needed.
• Future therapeutic studies should include fatigue as an outcome variable.
Chronic fatigue is a frequent and often disabling phenomenon
that occurs in patients with chronic inflammatory and autoim-
mune diseases, cancer, neurological diseases and a number of
other conditions in which inflammation and/or cellular stress
occurs. Fatigue may be defined as ‘an overwhelming sense of
tiredness, lack of energy, and feeling of exhaustion’.1 For the
individual, as well as for society, it is important to gain
knowledge of the mechanisms through which fatigue is gener-
ated, and to develop effective treatment strategies.
Chronic fatigue syndrome (CFS)/myalgia encephalomyelitis
(ME) is a condition characterized by chronic fatigue and in
which no underlying disease or condition can be identified.
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However, in contrast to popular media reports and beliefs,
most people with chronic fatigue have an underlying primary
disease other than CFS/ME, with the latter reported in 02–
04% of subjects in community-based studies, and 26% of
patients in primary care.2,3
There is a complex inter-relationship between mental
depression, pain and fatigue. Also, sleep disorders in general,
and disrupted sleep in dermatological disorders such as atopic
dermatitis, have been linked to daytime sleepiness.4 However,
it is outside the scope of this review to cover these important
psychosocial aspects of fatigue in depth.
Fatigue varies in intensity between patients, and may be so
profound that it severely interferes with activities of daily liv-
ing, leading to long-standing sick leave and disability. Many
patients with chronic diseases consider fatigue their most trou-
blesome challenge.5
The frequently reported lack of an association between fati-
gue and disease activity in many studies is a paradox, and
apparently goes against common beliefs and conceptions.6 It
is clear that social and psychological factors play a role, but
the paradox may have a foundation in genetic and molecular
mechanisms that are crucial for the generation and regulation
of fatigue.7 Emerging evidence points to the innate immune
system as an important ‘fatigue generator’, brought on by
invading pathogens, autoimmune diseases, cancer or other
‘danger-signals’, as well as cellular stress responses.8
Many dermatological diseases and conditions demonstrate
inflammatory or autoimmune features, suggesting that fatigue
would be an accompanying phenomenon in a number of
chronic skin diseases. Also, psoriasis shares common pathways
of immune signalling with other inflammatory diseases
including psoriatic arthritis and rheumatoid arthritis (RA),
such as the interleukin (IL)-23/T helper cell (Th)17 axis.9–12
The proinflammatory cytokine IL-23 orchestrates T-cell-depen-
dent pathways of inflammation, and of special importance is
activation of the T-cell subtype Th17, which produces IL-17
and other proinflammatory cytokines.13,14
From this perspective, one would expect fatigue to be
common in dermatological diseases, but the literature on this
matter is sparse and deals mainly with the effect of biologi-
cal agents on fatigue reported as quality-of-life measures. It
is therefore both important and challenging to explore the
extent of this problem and identify how – and if – this
phenomenon interferes with the lives of patients with such
diseases.
What is fatigue?
Fatigue is a poorly understood phenomenon. It is abstract in
nature and has been described as ‘like water it slips away and
cannot be grasped’.15 Although everyone seems to recognize
it, fatigue is often less focused on, overlooked or underesti-
mated by clinicians,5,16 which may reflect there being no spe-
cific treatment for chronic fatigue.17
While fatigue is difficult to define and treat, it is also a
challenge to measure. Making it even more complex, there is
conceptual disagreement about whether chronic fatigue can be
consider a unidimensional phenomenon, or whether several
dimensions or subscales of fatigue exist, such as physical fati-
gue, muscular fatigue, mental fatigue, cognitive fatigue etc.
Arguments for the first view are that fatigue is a universal and
global experience that to varying degrees interferes with – or
has an impact on – different aspects of human life, including
traits or attributes associated with the disease. Arguments for
the latter comprehension of fatigue are that fatigue is a phe-
nomenon that more or less specifically influences the muscles,
brain, mood, initiative, physical activity etc., and should
therefore be considered a separate feature.18
Fatigue interferes with several aspects of life including emo-
tional, physical and social functioning. The burden of chronic
fatigue on society is high, primarily due to medical expenses,
sick leave and loss of work.19,20 In a qualitative study of
patients with primary Sjӧgren syndrome (pSS) where the
effects of medications on fatigue were examined, two themes
emerged after individual interviews.21 Patients clearly differen-
tiated fatigue from normal tiredness and described ‘a heavy
resistant body and ever present lack of vitality’ and ‘an unpre-
dictable, uncontrollable fluctuation in fatigue’. This differs
from the normal tiredness everyone feels after being exposed
to mental and physical stress, and fatigue does not respond to
rest as in a healthy individual. Chronic fatigue is therefore not
to be confused with tiredness.
Biological mechanisms of fatigue
A highly relevant model for fatigue may be sought in the so-
called ‘sickness behaviour’, which represents an adaptive and
complex response in humans and animals during the course
of an infection.22–24 Sick individuals demonstrate loss of appe-
tite, initiative, grooming and interest in other individuals.
They develop sleepiness and withdraw from normal social
activities.25 Fatigue is a prominent and dominant feature of
this response. Sickness behaviour seems to be deeply con-
served throughout evolution and, as such, it is not a maladap-
tive response but a subconscious strategy for the survival of
the individual and the species (the genome) during viral and
bacterial infections.
Activation of the innate immune system, which is found in
all plant and animal life and which provides the immediate host
immune response to infection and other immunological ‘dan-
ger’, may be a key regulator of fatigue in both acute and chronic
conditions. A number of studies show that sickness behaviour is
associated with proinflammatory cytokines such as IL-1b, IL-6
and tumour necrosis factor (TNF)-a.23,26 Among these
cytokines, IL-1b seems to have a pivotal role.27 IL-1b possesses
an early and strong proinflammatory effect and is secreted
mainly by activated monocytes, macrophages and dendritic
cells.28–30 IL-1b also reaches neuronal cells in the brain where it
binds to specific IL-1 receptors not causing inflammation, but
instead triggering the behavioural response.22,31
There is substantial experimental evidence from animal
models for an essential role of IL-1b in promoting sickness
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behaviour. IL-1b is rapidly transported through the blood–
brain barrier in injected animals, followed by rapid upregula-
tion of both IL-1 receptor antagonist and IL-1RI in the
brain.32–35 Also, injection of lipopolysaccharide into the
abdominal cavity activates lipopolysaccharide receptors on the
vagal nerve. Through neuronal signalling, this leads to produc-
tion of IL-1b in the brain, which is followed by the animal
exhibiting sickness behaviour.36 IL-1RI knockout mice are
resistant to the sickness-inducing effects of IL-1b.31 All these
observations point strongly to IL-1b as a key factor for sick-
ness behaviour and fatigue.
In humans, blockade of IL-1 in both RA and pSS results in
reduced fatigue.37 Also, a number of studies in different dis-
eases have demonstrated beneficial effects on fatigue by all bi-
ologics given (i.e. anti-TNF-a, anti-IL-6, anti-CD20 and the
cytotoxic T-lymphocyte-associated protein 4 Ig fusion protein,
abatacept).38–41
Oxidative stress is observed in acute and chronic inflamma-
tory diseases, and an association between chronic fatigue and
measures of oxidative stress has been demonstrated in CFS/ME
and systemic lupus erythematosus (SLE).42,43 There are no
such studies in dermatological disorders. Oxidative stress
results from an imbalance in which reactive oxygen species
(ROS) dominate over antioxidant defences.44–46 ROS are
important in the first line of defence against infections, as they
kill pathogens engulfed in cellular phagolysosomes.47 Chronic
inflammation causes a prolonged state of increased oxidative
stress, as reported in several diseases including psoriasis.48–51
Oxidative stress is part of the innate immune response and
is triggered by activation of pattern-recognition receptors on
innate immune cells such as macrophages and granulocytes.
To protect against the harmful effects of free radicals, cells
have developed a highly efficient system for combating the
cellular stress imposed by these reactive intermediates.8 The
exact mechanism for how oxidative stress is associated with
fatigue is unknown, but could involve activation of genes
important for cellular viability and protection. These genes
might also be responsible for development of fatigue across
different disease groups such as chronic inflammatory, neuro-
degenerative and neoplastic diseases.7
How to measure fatigue
Objective markers of fatigue do not exist, and all fatigue
instruments are based on self-reporting. Some tests attempt to
measure multiple aspects of fatigue, whereas others use a sin-
gle unidimensional approach.52 Also, some fatigue instru-
ments are designed to be used in specific diseases and thus
include disease-specific variables, for example the Parkinson
Fatigue Scale,53 Fatigue Impact Scale for multiple sclerosis54
and Profile of Fatigue for pSS.55 Other instruments are generic
and may be used across different disease entities, for example
the Fatigue Severity Scale (FSS)56 and the Functional Assess-
ment of Chronic Illness Therapy Fatigue subscale (FACIT-F).57
An overview of selected fatigue instruments is given in
Table 1.
In patients with psoriasis, studies of fatigue have been
assessed mainly by the use of the medical outcomes study short
form 36-item (SF-36) health survey.58 Only three studies have
used FACIT-F.59–61 The SF-36 health survey is a 36-item general
health status instrument. It contains subscales for eight domains,
where the Vitality subscale is supposed to cover energy and fati-
gue.58 A change of 3 or more points in the SF-36 Vitality sub-
scale score is considered clinically meaningful.62 The FACIT-F
self-administered questionnaire, originally developed to assess
fatigue associated with anaemia in patients with cancer, includes
13 questions regarding the impact of fatigue on patients’ activi-
ties over the past 7 days.57 The FACIT-F scores ranges from 0 to
52, with lower scores indicating more fatigue. A change in score
of at least 3 points is considered to be a minimally clinically
important difference.63
Fatigue in chronic diseases
Fatigue is the defining feature of CFS/ME. The syndrome is
diagnosed when no other disease or underlying condition can
be identified.64 No main causes of the syndrome have been
agreed upon, but a dominant hypothesis is that CFS is a con-
dition caused by the interaction between a common viral
infection and individual susceptibility factors such as genetic
and immune system dysfunction.65
Table 1 Selected generic self-reported fatigue instruments
Name of scale Dimension What is assessed No. of scale items No. of subscales Scale type
Fatigue Severity Scale56 Unidimensional Impact and
functional outcomes
9 1 7-point Likert
Fatigue Visual Analogue Scale110 Unidimensional Severity 1 1 Visual analogue
Functional Assessment of
Chronic Illness Therapy
Fatigue Scale (FACIT-F)57
Unidimensional Severity and impact 13 1 5-point Likert
Medical Outcomes Study
Short Form 36-item scale (SF-36)58
Multidimensional Severity 36 8 3–6-point
Likert, yes/no
Multidimensional Fatigue
Inventory (MFI-20) scale111
Multidimensional Severity and impact 20 5 7-point Likert
Multidimensional Assessment
of Fatigue (MAF)112
Multidimensional Severity and impact 16 4 4–10-point Likert
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Fatigue accompanies inflammation and is frequently
reported among patients with a wide range of chronic inflam-
matory conditions. The prevalence of fatigue in patients with
RA, defined as a score of > 20 on the fatigue visual analogue
scale, was reported to be 41% in one study,66 and fatigue is
among the most commonly reported phenomena in multiple
sclerosis, pSS and SLE.67–70 In inflammatory diseases, as well
as in cancer-related fatigue, the fatigue has sometimes been
related to altered or increased proinflammatory cytokine pro-
duction.71,72 However, in general there seems to be a poor
correlation between disease activity and the severity of
fatigue.6,73–75 Lee et al.76 postulated that among patients with
RA there is a large subgroup with low levels of systemic
inflammation and low disease activity, yet high levels of fati-
gue and pain. This could be consistent with a chronic nonin-
flammatory central pain syndrome as seen in fibromyalgia,
which is a condition also associated with high levels of fati-
gue, pain and sleep problems.77 The underlying pathogenic
mechanism, as compared with those with high disease activity
inflammatory burden and high fatigue scores, could therefore
be somewhat different.
Cancer-related fatigue affects both patients with cancer and
cancer survivors.78 There are no major differences in fatigue
depending on cancer type, origin and disease stage.79 Interest-
ingly, cancer-related fatigue worsens during treatment with
cytostatic agents and radiation therapy, and may persist for years
in some cancer survivors after the cancer has been eradicated.80
Parkinson disease and cerebral stroke are examples of neuro-
logical conditions with no clear inflammatory component, and
in which fatigue is common and may be debilitating.81 In cere-
bral stroke, it is possible that there is a disturbance of neuronal
circuits within the basal ganglia, thalamus and cerebral cortex,
while the fatigue mechanisms in neurodegenerative diseases are
less clear, but might well be due to cellular stress responses.82,83
Confounding factors
Depression, sleep disorders and pain are confounding factors
to fatigue. Fatigue is strongly associated with depression and
vice versa.84–86 There is an overlap in symptomatology
between fatigue and depression, but fatigue also appears with-
out depression.68 Both depression and fatigue in chronic
inflammatory disorders, as well as in depressive diseases, have
been associated with proinflammatory cytokines.87 Intrigu-
ingly, patients with chronic fatigue are less responsive to anti-
depressant drugs than depressed patients.88 Notably, several
biological agents used in chronic inflammatory disorders have
shown improvement in both depression and fatigue scores.89–91
Some evidence indicates that IL-1 and TNF-a may play a role in
the regulation of sleep.92 The clinically interesting question is
why these behavioural alterations present more easily and are
more severe in some individuals than in others.
Fatigue in psoriasis
Psoriasis vulgaris (plaque psoriasis) is an immune-mediated
chronic inflammatory disease affecting about 2% of the
world’s population.93 The inflammation is thought to be a
consequence of a T-cell-mediated immune response to an as-
yet unidentified autoantigen. Several lines of evidence suggest
an important role for IL-17 in the pathogenesis of psoriasis, as
well as in psoriatic arthritis and other chronic inflammatory
disorders.94 Psoriasis may have a major impact on a patient’s
life, especially when the disease is moderate to severe.95
While psychosocial aspects have been widely studied in der-
matological diseases, less is known about fatigue.96 For an
overview of genuine studies of fatigue in psoriasis, see
Table 2. The majority of data regarding this phenomenon are
derived from the Vitality subscale of the SF-36, a general mea-
sure of health-related quality of life. This subscale consists of
only four questions, providing some indications of fatigue
(Table 1). One study using the SF-36 in dermatological outpa-
tient clinics in Norway reported significantly lower scores than
the general norms on eight subscales of the SF-36, and higher
levels of psoriasis-specific symptoms (itching, burning, scal-
ing, suppuration, stinging and joint pain) were significantly
related to all of the SF-36 subscales.97 It was not stated
whether some patients also had psoriatic arthritis.
Table 2 Genuine studies on fatigue in psoriasis
Study Design Fatigue instrument Outcome (mean)
Rapp (1999)113 Postal questionnaire study where scores of 317 patients
with psoriasis were compared with those from 10
different health conditions
SF-36 VS Vitality subscale 454
Wahl (2000)97 283 patients with psoriasis were included and scores
compared with general populations norms
SF-36 VS Vitality subscale 482
Evers (2005)96 Questionnaires administered to 128 outpatients with
psoriasis
VAS-Fatigue VAS-Fatigue 38
Verhoeven (2007)114 Postal questionnaire study where scores of 112 patients
with psoriasis registered in general practice were
compared with those from nine other skin conditions
VAS-Fatigue VAS-Fatigue 32, 28% reported
severe fatigue (VAS > 5)
Jankovic (2011)115 Questionnaires administered to 110 outpatients with
psoriasis
SF-36 VS Vitality subscale 489
SF-36 VS, Medical Outcomes Study Short Form 36-item scale (SF-36) Vitality subscale; VAS, visual analogue scale.
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The prevalence of psoriatic arthritis in patients with psoriasis
is estimated to be as high as 30%.98 Few comparative studies of
health-related quality-of-life measures between patients with
psoriasis with and without arthritis have been performed. In
one study, patients with psoriasis without arthritis were found
to have less fatigue, as measured by the FSS and the Vitality sub-
scale of the SF-36, compared with patients with arthritis.99 In
this study, the mean Dermatology Life Quality Index of patients
with psoriasis was 77, indicating a moderate effect on patients’
lives. These findings are in contrast to the 2005 Spring US
National Psoriasis Foundation Quality of Life study, where no
differences were found in overall health-related quality of life
between these groups.100 This study was conducted by tele-
phone interviews, which might affect the quality of the data
collected. To what degree arthritis influences fatigue in patients
with psoriasis is therefore difficult to assess.
The majority of data on fatigue in patients with psoriasis
arises from therapeutic clinical trials in which patients with
arthritis have frequently been included, and these studies often
lack information on the number of subjects with arthritis (for
an overview see Table 3).38,59–61,101–109 Patients who were
included generally had moderate-to-severe psoriasis with a
mean Psoriasis Area and Severity Index (PASI) > 14. All thera-
peutic studies in psoriasis employing biological agents have
demonstrated a beneficial effect on the Vitality subscale of the
SF-36. Only three studies used the FACIT-F, but revealed a
clinically meaningful reduction of fatigue with the TNF-a
inhibitors adalimumab or etanercept.59–61 Tyring et al.
reported less fatigue as measured with the FACIT-F, which
was associated with improvements in joint and skin pain with
the use of etanercept. In this study, up to 35% of the patients
included had arthritis, and it was debated whether the effect
of etanercept on fatigue could be attributed to an effect on
psoriatic arthritis.91
To the best of our knowledge, no studies have investigated
fatigue in relation to disease activity in patients with psoriasis
who did not have arthritis. Also, because most patients with
psoriasis have low C-reactive protein or erythrocyte sedimen-
tation rate, it is difficult to evaluate the influence that psoriatic
inflammation might have on fatigue. Finally, the prevalence
and the degree of fatigue in a general population with psoria-
sis compared with a healthy control group remains to be
studied.
Conclusions
Fatigue is an important feature of all inflammatory diseases. In
psoriasis and other dermatological diseases, knowledge of fati-
gue is sparse and could represent a major but hidden problem
in a considerable number of patients with psoriasis. Moreover,
is it not known whether fatigue in patients with psoriasis is
related to the extent of the disease (PASI scores) or other dis-
ease characteristics. It is therefore important to determine the
prevalence, severity and impact of fatigue because this will
add to the clinician’s understanding and management of
patients with psoriasis. Also, future therapeutic studies should
include fatigue as an outcome variable.
The psychological and social factors that influence fatigue
are outside the scope of this review. These issues need to be
reviewed and synthesized as part of future research projects.
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